BioDelivery Services: BEMA Fentanyl Submitted for Marketing Authorization in Taiwan; BDSI to receive $300,000 milestone payment (BDSI) 0.88 : Co announced that TTY Biopharm, BDSI's commercial partner for BEMA Fentanyl in Taiwan, has submitted a New Drug Application for marketing authorization of BEMA Fentanyl to the Taiwan Food and Drug Administration. In October 2010, BDSI granted TTY the exclusive rights to develop and commercialize BEMA Fentanyl. Under terms of the agreement, BDSI is eligible for milestone payments of up to $1.3 mln, which included an upfront payment of $300,000. This NDA submission results in an additional milestone payment of $300,000 to BDSI. In addition, upon regulatory approval, BDSI will receive an ongoing royalty based on net sales.
Market Data 
Markets 
AI
